Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 419-425

  Aroui, Sonia ^a,b   Brahim, Souhir ^a   Waard, Michel De ^b   Kenani, Abderraouf ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

Cell penetrating peptide; Doxorubicin; Drug delivery systems; Drug resistance

Indexed keywords

DOXORUBICIN; PENETRATIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL KILLING; CELL LINE; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CHO CELL; COLORIMETRY; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR CELL; TUMOR RESISTANCE; VALIDITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DOXORUBICIN; HUMANS; PEPTIDE FRAGMENTS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

CRICETULUS GRISEUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PENE;

EID: 73149085053     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.073     Document Type: Article

References (28)

1. Longely D.B., and Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 205 2 (2005) 275-292
2. Gottesman M.M. Mechanisms of drug resistance. Ann. Rev. Med. 53 (2002) 615-627
3. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
4. Nielsen D., Maare C., and Skovsgaard T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27 2 (1996) 251-255
5. Binashi M., Bigioni M., Cipollone A., Rossi C., Goso C., Maggi C.A., Capranico G., and Animati F. Anthracyclines: selected new developments. Curr. Med. Chem. 1 (2001) 113-130
6. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62 (1993) 385-427
7. Massing U., and Fuxius S. Liposomal formulations of anticancer agents: selectivity and effectiveness. Drug Resist. Updat. 3 (2000) 171-177
8. Ruby M., Konak C., and Ulbrich K. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J. Control Release (2005) 137-148
9. Tewes F., Munnier E., Antoon B., Nagaboni O.L., Cohen J.S., Marchais H., Douziech E., Soucé L.M., Dubois P., and Chourpa I. Comparative study of doxorubicin-loaded poly(latide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur. J. Pharm. Biopharm. (2007) 02-016
10. Di Stefano G., Lanza M., Kraz F., Merina L., and Fiume L. A noval method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur. J. Pharm. Sci. 23 (2004) 393-397
11. Di Stefano G., Fiume L., Domenicali M., Busi C., Chieco P., Kratz F., Lanza M., Mattioli A., Pariali M., and Bernardi M. Doxorubicin coupled to lactosaminated albumin: effect on rats with liver fibrosis and cirrhosis. Dig. Liv. Dis. 38 (2006) 404-408
12. Zorko M., and Langel U. Cell penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug. Deliv. Rev. 57 (2005) 529-545
13. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
14. Derossi D., Chassaing G., and Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8 (1998) 84-87
15. Henning K., Natisha M., Richard J.I., and Kathryn M.S. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs 18 (2007) 419-425
16. Sharma R., Arnold L., and gulliya K.S. Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells. Anticancer Res. 15 (1995) 295-304
17. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34 (2008) 378-390
18. Aroui S., Ram N., Appaix F., Ronjat M., Kenani A., Pirollet F., and De Waard M. Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm. Res. 10 (2008) 1007 (11095-008-9782-9801)
19. Shen F., Chu S., Bence A.K., Bailey B., Xue X., Erickson P.A., Montrose M.H., Beck W.T., and Erickson L.C. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J. Pharmacol. Exp. Ther. 324 (2008) 95-102
20. Temsamani J., and Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today 9 (2004) 1012-1019
21. Saar K., Lindgren M., Hansen M., Eiríksdóttir E., Jiang Y., Rosenthal-Aizman K., Sassian M., and Langel U. Cell-penetrating peptides: a comparative membrane toxicity study. Anal. Biochem. 345 1 (2005) 55-65
22. Ziegler A., and Seelig J. High affinity of the cell-penetrating peptide HIV-1 Tat-PTD for DNA. Biochemistry 46 (2007) 8138-8145
23. Mazel M., Clair P., Rousselle C., Vidal P., Scherrmann J.M., Mathieu D., and Temsamani J. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 2 (2001) 107-116
24. Castex C., Merida P., Blanc E., Clair P., Rees A.R., and Temsamani J. 2 Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance. Anticancer Drugs 6 (2004) 609-617
25. Mae M., and Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 6 (2006) 509-514
26. van Hensbergen Y., Broxterman H.J., Elderkamp Y.W., Lankelma J., Beers J.C., Heijn M., Boven E., Hoekman K., and Pinedo H.M. A doxorubicin CNGRC-peptide conjugate with prodrug properties. Biochem. Pharmacol. 63 (2002) 897-908
27. Gusarova G.A., Wang I.C., Major M.L., Kalinichenko V.V., Ackerson T., Petrovic V., and Costa R.H. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 117 (2007) 99-111
28. Hirose M., Takatori M., Kuroda Y., Abe M., Murata E., Isada T., Ueda K., Shigemi K., Shibazaki M., Shimizu F., Hirata M., Fukazawa K., Sakaguchi M., Kageyama K., and Tanaka Y. Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells. J. Pharmacol. Sci. 106 (2008) 107-113